logo
Commentary: This health insurance clash is a chance to fix issues in Singapore's healthcare system

Commentary: This health insurance clash is a chance to fix issues in Singapore's healthcare system

CNA14 hours ago

SINGAPORE: Tensions had been simmering for months, with insurer Great Eastern encouraging its panel doctors and agents to avoid Mount Elizabeth and Mount Elizabeth Novena hospitals and instead seek care elsewhere. Things came to a sudden head on Jun 17 when the insurer announced it was suspending pre-authorisation certificates at both hospitals, citing higher charges with no discernible differences in clinical outcomes.
This was unprecedented in the decades-long history between healthcare payers and providers. It is a game-changing salvo in Singapore's healthcare landscape.
Now, social media is awash with accusations of 'greedy' insurers and 'predatory' hospitals. Doctors and patients scramble to shift care to other facilities for fear of rejected claims later on.
IHH, the operator of the two hospitals and by far the largest private healthcare group in Singapore, argued that the Mount Elizabeth Hospitals 'house facilities and equipment that allow specialists to manage patients and perform surgeries that are not available at other hospitals' and catered to more complex patients, thus justifying higher charges.
The Ministry of Health (MOH) stated it was seeking clarification from Great Eastern, cautioning that the insurer must ensure 'policyholders continue to be able to access the full benefits of their policies in accordance with the terms and conditions for claims, as stated in their policy contracts'.
What should we make of all this? There are two realities to recognise and two next steps to consider.
HARD REALITIES OF SINGAPORE'S HEALTHCARE LANDSCAPE
The first reality is the clear mutual dependence between insurers and private healthcare providers.
Without private providers, there would be no need for private health insurance. Without private health insurance, many may not be able to afford private healthcare. That said, mutual dependence does not mean mutual interests.
Insurers pool risk by collecting premiums from many to cover the claims of a smaller subset, but they cannot simply be passive conduits of our money without value-adding. They seek to optimise value for claims paid out, and managing the fees charged would be expected.
Conversely, private sector doctors and facilities would seek to maximise fees and charges – within ethical boundaries – for example in opportunities to sell branded drugs instead of generics or use the latest equipment when the conventional would suffice for a good outcome. Doctors' fees, traditionally 50 per cent of the total bill, have been moderated after years of insurer interventions, such as encouraging use of panel doctors with pre-agreed fees or imposing fee guidelines.
Facility fees, on the other hand, have largely escaped scrutiny and today can make up two-thirds of the total bill. It is unsurprising that insurers have now turned their attention to these.
The second reality is that healthcare costs are rising unsustainably and left unchecked, this will be bad for everyone.
The cost of healthcare insurance benefits – which is a useful proxy for private healthcare spending – has increased in Singapore by about 12 to 13 per cent every year in the last three years. Minister for Health Ong Ye Kung has stated that the government healthcare budget doubled in the last decade, jumping from S$9 billion in 2015 to S$21 billion this year and is projected to reach more than S$30 billion by 2030.
BETTER PROTECTION FOR HEALTHCARE CONSUMERS
Two actions taken in unison might help with the way forward.
First, strengthen consumer protection. In the ongoing saga, it's surprising that policyholders have not publicly sought more reassurance from the insurer.
While Great Eastern has said policyholders 'can still receive treatment and submit claims as usual with no impact to their benefits', customers may need to pay upfront and be reimbursed some time after receiving care in the affected hospitals. But they will be hardly reassured of their benefits, without knowing if there could be disputes over services rendered and fees.
There should be, at least on an exceptional basis, an appeal process and mechanisms to enable pre-authorisation for patients with more complex needs, so the affected hospitals would still be accessible without worries about advance payments.
Should people be allowed to freely switch insurers? Due to underwriting at enrolment, this is fraught with challenges (particularly if one has been diagnosed with a health condition) and is not realistic in practice. MOH said in November 2024 that it ' does not believe that mandating full portability for IPs is the right solution '.
This leaves customers effectively captive with only two options: exiting private insurance with relying only on MediShield Life, or accepting new policy terms and premium increases, no matter how unjust these are perceived to be. Both are poor alternatives.
The former further stresses an already stretched public healthcare system and increases current and future funding commitments by the government which it may struggle to honour in prolonged economic downturns. The latter worsens public frustration with 'Big Business' and risks fomenting the perception of an elitist government pandering to commercial ahead of citizens' interests.
HELP PATIENTS MAKE BETTER DECISIONS
Second, focus on data and transparency for decision-making. No two patients are the same. Hence to fairly compare across doctors and facilities, multiple other data points are collected for risk adjustment.
Consider two surgeons each with a patient undergoing gallbladder removal surgery: One patient has kidney and heart issues and the other an otherwise healthy marathon runner. They would have very different care protocols and journeys, such as the need for post-operative intensive care, despite going through the same surgery.
With appropriate risk adjustments, policymakers, insurers and healthcare providers can assess and compare the quality and cost-effectiveness of the surgeons and facilities despite them having very different patient profiles.
Customers would really prioritise only three factors for healthcare services: clinical outcome, patient experience such as waiting time and service hospitality, and price. In choosing insurance products, beyond the current terms offered, customers would want to know the historic rates of declining claims, the number of disputes between insurer and policy holder as well as the patterns of premium adjustments over the years.
MOH already puts out comparisons of insurers' lifetime premiums, sample contracts, claims processing duration and pre-authorisation turnaround times. Combining these with clinical data is necessary now.
Surely in a Smart Nation, all this data could be collected, analysed and made available so that all stakeholders can make better decisions.
We all want the best available for the lowest costs, and in finding value, such data would greatly aid customer selection of the insurers that best meet their needs and budgets. Different facilities do have different sophistication and expertise and these should be aligned to the needs of the specific patients.
GOVERNMENT'S ROLE IN TRANSPARENCY
The role of the government deserves re-examination. Singapore traditionally prefers light-touch regulation, opting for market mechanisms instead.
Former health minister Khaw Boon Wan used to describe healthcare as the classic case of market failure and said that when the healthcare market fails, the government should explore how to step in to make the market work better as a first step.
One condition for a perfect market is typically information transparency and the government has a role in enabling meaningful public availability of information.
Strong government encouragement of both insurers and providers (doctors and facilities) to collect data in standardised manners and make it available is essential.
Any data framework and analytics won't be perfect – especially when we first start, but anything would be better than the current 'he says, she says' situation with customers caught in the middle with no way of understanding whose arguments are founded.
Facilitated negotiations would also help tremendously. MOH already has a regular platform to facilitate discussion across insurers, facilities and doctors on industry-wide issues. It is timely to ask how this can be made more effective, perhaps by involving the insurance regulator, the Monetary Authority of Singapore (MAS).
A combined MOH-MAS team with expert knowledge and regulatory powers could convene the stakeholders to find effective solutions, without resorting to heavy-handed policy that could crush innovation and compel the industry into a downward spiral with only pricing as the differentiator.
DON'T WASTE A 'GOOD CRISIS'
The dispute between Great Eastern and IHH is a harbinger of worse things to come if this degenerates into a cesspool of misinformation and wild accusations.
Yes, healthcare costs are escalating beyond society's ability to cope and effective solutions are needed. Yes, all parties seek and will need a fair profit to continue. But the public interest must be paramount.
Insurers and healthcare providers need to recognise the mutual dependence despite divergent interests, and work together. Customer rights must also be better and more forcefully represented to balance the power of the insurers and providers. The government should step in to bring the disputing parties together in constructive dialogue and actionable solutions starting with better data, better analytics and better decision-making.
The pragmatic Singapore way is not to waste a 'good crisis', but seize the opportunity to correct long-festering perversions in the current system. Else, patients and policyholders could get hurt while public confidence in both the healthcare and insurance sectors erodes, to the ultimate detriment of all of us.
Jeremy Lim is a public health physician and author of Myth or Magic - The Singapore Healthcare System.
Taufeeq Wahab is a doctor and senior preventive medicine resident with the National University Health System (NUHS).

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hong Kong-listed China Medical System seeks secondary listing on SGX
Hong Kong-listed China Medical System seeks secondary listing on SGX

Business Times

time8 hours ago

  • Business Times

Hong Kong-listed China Medical System seeks secondary listing on SGX

[SINGAPORE] Hong Kong-listed China Medical System (CMS) is seeking a secondary listing on the mainboard of the Singapore Exchange (SGX) in July this year. CMS is a specialty pharma with a focus on sales and marketing in China, with capabilities across the full lifecycle of drug development, from identifying clinical needs to research and development (R&D) regulatory approval, and commercialisation. It has been listed on the Stock Exchange of Hong Kong since 2010. The pharmaceutical company expects the secondary listing will help it deepen its presence in South-east Asia and 'tap into a new and sophisticated investor base in Singapore'. CMS said it is looking to replicate its success in South-east Asia – building on the proven track record attained in China's pharmaceutical industry. 'This region, with a population of nearly 700 million, is experiencing surging pharmaceutical demand due to rapid economic growth, the rise of the middle class, ageing population, and the increasing burden of non-infectious diseases,' it said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Its financial performance in 2023 and 2024 were hit by China's volume-based procurement (VBP) policy – three of its products were included in the VBP list. This policy aims to lower the prices of drugs with generic competition, by guaranteeing certain procurement volumes from public hospitals at significantly reduced prices through a bidding process. But CMS had a top-line rebound in H2 2024, driven by progress in commercialising innovative drugs and the continued growth of non-VBP exclusive products. The company moved towards innovative drugs, given that they typically enjoy a pricing advantage due to their exclusiveness, novelty and quality, and are supported by favourable government policies. It expects growth momentum will accelerate on the back of the replenishment of its pipeline of innovative drugs to about 40 products as at Dec 31, 2024. It noted four key platforms to scale its pharmaceutical ecosystem across Asia-Pacific. CMS R&D is involved in drug discovery and development targeting global markets, while PharmaGend is a development and manufacturing platform for regional manufacturing and supply. It also has Rxilient Health, a Singapore-headquartered entity focused on registration and commercialisation in South-east Asia and a Singapore venture arm, which makes strategic investments to support regional pharma innovation. In a statement on Jun 24, CMS said the proposed listing will not involve issuance of new shares, and the shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. Singapore is its regional headquarters for its South-east Asia and Middle East business, the company said. The announcement follows the news of several new listings on SGX – software services provider Info-Tech Systems, a data centre real estate investment trust (Reit) by Japanese telco Nippon Telegraph and Telephone (NTT), and a spin-off of mainboard-listed construction company Lum Chang Holdings' interior fit-out business. Info-Tech Systems, whose shares are expected to begin trading on Jul 4, is the first SGX mainboard listing in two years. NTT DC Reit, which will have a portfolio of six of NTT's data centre assets, will likely be the largest Singapore Reit listing in a decade. Meanwhile, interior fit-out business Lum Chang Creations is looking to list on the Catalist board.

Singapore to raise age limit for first-time blood donors from 60 to 65
Singapore to raise age limit for first-time blood donors from 60 to 65

CNA

time9 hours ago

  • CNA

Singapore to raise age limit for first-time blood donors from 60 to 65

SINGAPORE: In a move to expand Singapore's pool of blood donors, the Health Sciences Authority will raise the maximum age for first-time blood donors from 60 to 65, Health Minister Ong Ye Kung announced on Saturday (June 28). The rule relaxation, which kicks in on Jan 1, 2026, is aligned with longer life expectancy and better health in older age, said Mr Ong. He also said local data showed that adverse donor reaction actually decreases with age among Singapore's first-time donors up to the current limit of 60 years old. "There is no reason to believe that once you cross 60 years old, suddenly the adverse reaction prevalence rate is going to shoot up," said Mr Ong during an event at Marina Bay Sands marking World Blood Donor Day. Currently, first-time whole blood donors in Singapore must be aged 60 or below. Repeat donors can donate until they are 65, or beyond if they meet health criteria and have donated recently. Under the revised policy, healthy people will be able to donate blood for the first time until the age of 65, bringing Singapore in line with jurisdictions such as Hong Kong, Taiwan, Ireland, the Netherlands, South Korea and the United Kingdom. BLOOD BANK CHALLENGES Mr Ong, who is also the Coordinating Minister for Social Policies, noted that Singapore faces structural challenges in maintaining a stable blood supply. An ageing population is driving up demand for blood products, while the pool of eligible donors is shrinking, he said. The number of new blood donors has also declined, from over 20,000 in 2013 to around 18,000 in 2024. At the same time, demand is rising, said Mr Ong. Last year, more than 35,000 patients in Singapore received blood transfusions, which are needed for surgeries, cancer treatment and childbirth complications. "Each blood donation saves up to three lives," said Mr Ong. But if blood stocks run low, surgeries will be postponed, treatments delayed and lives could be at risk, he warned. Singapore also contends with seasonal fluctuations in supply, with donor numbers falling during festive periods, school holidays and long weekends when many travel overseas. Early last year, Group O blood stocks in Singapore dropped to critical levels as the country's stockpile stood at less than six days' worth of blood. A personal appeal by Mr Ong, he said, resulted in the blood stock rising by almost 2.3 times in a week. Mr Ong said that this experience showed how people are willing to step forward, adding that authorities would work to make donation more convenient, and to minimise rejection of willing donors. ENCOURAGING MORE TO STEP FORWARD Beyond the policy change, Mr Ong shared that he himself had been unable to donate blood for years because he had lived in the UK during the 1980s, when there was a risk of exposure to Variant Creutzfeldt-Jakob Disease (vCJD) - also known mad cow disease - a rare brain disorder linked to contaminated beef. However, a revision in donor guidelines now allows him to donate via apheresis, which he said makes the risk of blood contamination by vCJD "negligible". During donation by apheresis, only specific blood components like platelets or plasma are collected, while the rest is returned to the donor. Despite structural changes and policy reviews, Mr Ong stressed that the success of the national blood programme still hinges on community involvement. At the event on Saturday, over 2,000 champion blood donors were recognised, alongside 34 community organisations that had run donation campaigns, including student groups, businesses and even fan clubs of visiting pop stars. "Giving is a very joyous thing," said Mr Ong.

Commentary: This health insurance clash is a chance to fix issues in Singapore's healthcare system
Commentary: This health insurance clash is a chance to fix issues in Singapore's healthcare system

CNA

time14 hours ago

  • CNA

Commentary: This health insurance clash is a chance to fix issues in Singapore's healthcare system

SINGAPORE: Tensions had been simmering for months, with insurer Great Eastern encouraging its panel doctors and agents to avoid Mount Elizabeth and Mount Elizabeth Novena hospitals and instead seek care elsewhere. Things came to a sudden head on Jun 17 when the insurer announced it was suspending pre-authorisation certificates at both hospitals, citing higher charges with no discernible differences in clinical outcomes. This was unprecedented in the decades-long history between healthcare payers and providers. It is a game-changing salvo in Singapore's healthcare landscape. Now, social media is awash with accusations of 'greedy' insurers and 'predatory' hospitals. Doctors and patients scramble to shift care to other facilities for fear of rejected claims later on. IHH, the operator of the two hospitals and by far the largest private healthcare group in Singapore, argued that the Mount Elizabeth Hospitals 'house facilities and equipment that allow specialists to manage patients and perform surgeries that are not available at other hospitals' and catered to more complex patients, thus justifying higher charges. The Ministry of Health (MOH) stated it was seeking clarification from Great Eastern, cautioning that the insurer must ensure 'policyholders continue to be able to access the full benefits of their policies in accordance with the terms and conditions for claims, as stated in their policy contracts'. What should we make of all this? There are two realities to recognise and two next steps to consider. HARD REALITIES OF SINGAPORE'S HEALTHCARE LANDSCAPE The first reality is the clear mutual dependence between insurers and private healthcare providers. Without private providers, there would be no need for private health insurance. Without private health insurance, many may not be able to afford private healthcare. That said, mutual dependence does not mean mutual interests. Insurers pool risk by collecting premiums from many to cover the claims of a smaller subset, but they cannot simply be passive conduits of our money without value-adding. They seek to optimise value for claims paid out, and managing the fees charged would be expected. Conversely, private sector doctors and facilities would seek to maximise fees and charges – within ethical boundaries – for example in opportunities to sell branded drugs instead of generics or use the latest equipment when the conventional would suffice for a good outcome. Doctors' fees, traditionally 50 per cent of the total bill, have been moderated after years of insurer interventions, such as encouraging use of panel doctors with pre-agreed fees or imposing fee guidelines. Facility fees, on the other hand, have largely escaped scrutiny and today can make up two-thirds of the total bill. It is unsurprising that insurers have now turned their attention to these. The second reality is that healthcare costs are rising unsustainably and left unchecked, this will be bad for everyone. The cost of healthcare insurance benefits – which is a useful proxy for private healthcare spending – has increased in Singapore by about 12 to 13 per cent every year in the last three years. Minister for Health Ong Ye Kung has stated that the government healthcare budget doubled in the last decade, jumping from S$9 billion in 2015 to S$21 billion this year and is projected to reach more than S$30 billion by 2030. BETTER PROTECTION FOR HEALTHCARE CONSUMERS Two actions taken in unison might help with the way forward. First, strengthen consumer protection. In the ongoing saga, it's surprising that policyholders have not publicly sought more reassurance from the insurer. While Great Eastern has said policyholders 'can still receive treatment and submit claims as usual with no impact to their benefits', customers may need to pay upfront and be reimbursed some time after receiving care in the affected hospitals. But they will be hardly reassured of their benefits, without knowing if there could be disputes over services rendered and fees. There should be, at least on an exceptional basis, an appeal process and mechanisms to enable pre-authorisation for patients with more complex needs, so the affected hospitals would still be accessible without worries about advance payments. Should people be allowed to freely switch insurers? Due to underwriting at enrolment, this is fraught with challenges (particularly if one has been diagnosed with a health condition) and is not realistic in practice. MOH said in November 2024 that it ' does not believe that mandating full portability for IPs is the right solution '. This leaves customers effectively captive with only two options: exiting private insurance with relying only on MediShield Life, or accepting new policy terms and premium increases, no matter how unjust these are perceived to be. Both are poor alternatives. The former further stresses an already stretched public healthcare system and increases current and future funding commitments by the government which it may struggle to honour in prolonged economic downturns. The latter worsens public frustration with 'Big Business' and risks fomenting the perception of an elitist government pandering to commercial ahead of citizens' interests. HELP PATIENTS MAKE BETTER DECISIONS Second, focus on data and transparency for decision-making. No two patients are the same. Hence to fairly compare across doctors and facilities, multiple other data points are collected for risk adjustment. Consider two surgeons each with a patient undergoing gallbladder removal surgery: One patient has kidney and heart issues and the other an otherwise healthy marathon runner. They would have very different care protocols and journeys, such as the need for post-operative intensive care, despite going through the same surgery. With appropriate risk adjustments, policymakers, insurers and healthcare providers can assess and compare the quality and cost-effectiveness of the surgeons and facilities despite them having very different patient profiles. Customers would really prioritise only three factors for healthcare services: clinical outcome, patient experience such as waiting time and service hospitality, and price. In choosing insurance products, beyond the current terms offered, customers would want to know the historic rates of declining claims, the number of disputes between insurer and policy holder as well as the patterns of premium adjustments over the years. MOH already puts out comparisons of insurers' lifetime premiums, sample contracts, claims processing duration and pre-authorisation turnaround times. Combining these with clinical data is necessary now. Surely in a Smart Nation, all this data could be collected, analysed and made available so that all stakeholders can make better decisions. We all want the best available for the lowest costs, and in finding value, such data would greatly aid customer selection of the insurers that best meet their needs and budgets. Different facilities do have different sophistication and expertise and these should be aligned to the needs of the specific patients. GOVERNMENT'S ROLE IN TRANSPARENCY The role of the government deserves re-examination. Singapore traditionally prefers light-touch regulation, opting for market mechanisms instead. Former health minister Khaw Boon Wan used to describe healthcare as the classic case of market failure and said that when the healthcare market fails, the government should explore how to step in to make the market work better as a first step. One condition for a perfect market is typically information transparency and the government has a role in enabling meaningful public availability of information. Strong government encouragement of both insurers and providers (doctors and facilities) to collect data in standardised manners and make it available is essential. Any data framework and analytics won't be perfect – especially when we first start, but anything would be better than the current 'he says, she says' situation with customers caught in the middle with no way of understanding whose arguments are founded. Facilitated negotiations would also help tremendously. MOH already has a regular platform to facilitate discussion across insurers, facilities and doctors on industry-wide issues. It is timely to ask how this can be made more effective, perhaps by involving the insurance regulator, the Monetary Authority of Singapore (MAS). A combined MOH-MAS team with expert knowledge and regulatory powers could convene the stakeholders to find effective solutions, without resorting to heavy-handed policy that could crush innovation and compel the industry into a downward spiral with only pricing as the differentiator. DON'T WASTE A 'GOOD CRISIS' The dispute between Great Eastern and IHH is a harbinger of worse things to come if this degenerates into a cesspool of misinformation and wild accusations. Yes, healthcare costs are escalating beyond society's ability to cope and effective solutions are needed. Yes, all parties seek and will need a fair profit to continue. But the public interest must be paramount. Insurers and healthcare providers need to recognise the mutual dependence despite divergent interests, and work together. Customer rights must also be better and more forcefully represented to balance the power of the insurers and providers. The government should step in to bring the disputing parties together in constructive dialogue and actionable solutions starting with better data, better analytics and better decision-making. The pragmatic Singapore way is not to waste a 'good crisis', but seize the opportunity to correct long-festering perversions in the current system. Else, patients and policyholders could get hurt while public confidence in both the healthcare and insurance sectors erodes, to the ultimate detriment of all of us. Jeremy Lim is a public health physician and author of Myth or Magic - The Singapore Healthcare System. Taufeeq Wahab is a doctor and senior preventive medicine resident with the National University Health System (NUHS).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store